
|Articles|December 17, 2014
- Breast Cancer (Issue 1)
- Volume 1
- Issue 1
Immune Checkpoint Inhibition in Breast Cancer
Author(s)Edith A. Perez, MD
Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, comments on immune checkpoint inhibition for the treatment of breast cancer.
Advertisement
Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, comments on immune checkpoint inhibition for the treatment of breast cancer.
<<<
Articles in this issue
over 11 years ago
Breast Ultrasound Added to Mammography Increases Cancer Detectionover 11 years ago
Biomarker-Driven Trial of Novel Topo-1 Inhibitor Debutedover 11 years ago
Anti-Androgen Not for Male Cancers Aloneover 11 years ago
Obesity as a Risk Factor for Inflammatory Breast Cancerover 11 years ago
Advances in the Treatment of HER2-Positive Breast CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
4
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
5



























